Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
Cornelius Katona, Cara Katona
Neuropsychiatric Disease and Treatment (2014), pp. 349-349
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Gin S. Malhi, Darryl Bassett, Philip Boyce, et al.
Australian & New Zealand Journal of Psychiatry (2015) Vol. 49, Iss. 12, pp. 1087-1206
Closed Access | Times Cited: 728
Natural volatile oils derived from herbal medicines: A promising therapy way for treating depressive disorder
Yulu Zhang, Yu Long, Shuang Yu, et al.
Pharmacological Research (2020) Vol. 164, pp. 105376-105376
Closed Access | Times Cited: 140
The molecular pathophysiology of depression and the new therapeutics
Haihua Tian, Zhenyu Hu, Jia Xu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 65
Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases
Orkid Coskuner‐Weber, Ozan Mirzanli, Vladimir N. Uversky
Biophysical Reviews (2022) Vol. 14, Iss. 3, pp. 679-707
Open Access | Times Cited: 45
Faster, better, stronger: Towards new antidepressant therapeutic strategies
Olivia F. O’Leary, Timothy G. Dinan, John F. Cryan
European Journal of Pharmacology (2014) Vol. 753, pp. 32-50
Closed Access | Times Cited: 93
Major depressive disorder: mechanism-based prescribing for personalized medicine
Thomas Lapolla, Philip Saltiel, Daniel Silvershein
Neuropsychiatric Disease and Treatment (2015), pp. 875-875
Open Access | Times Cited: 86
Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis
Jianyang Lin, Mingyan Jiang, Zhoumi Kan, et al.
Journal of Affective Disorders (2014) Vol. 168, pp. 430-438
Closed Access | Times Cited: 64
Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant
Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, et al.
Pharmacological Reports (2017) Vol. 69, Iss. 4, pp. 595-601
Closed Access | Times Cited: 61
Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis
Paula L. Jacobsen, Atul R. Mahableshwarkar, William Palo, et al.
CNS Spectrums (2015) Vol. 21, Iss. 5, pp. 367-378
Open Access | Times Cited: 60
A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder
Andrea Fagiolini, Umberto Albert, Laura Ferrando, et al.
International Clinical Psychopharmacology (2020) Vol. 35, Iss. 3, pp. 137-146
Open Access | Times Cited: 35
An Overview of Vortioxetine
Alan F. Schatzberg, Pierre Blier, Larry Culpepper, et al.
The Journal of Clinical Psychiatry (2014) Vol. 75, Iss. 12, pp. 1411-1418
Open Access | Times Cited: 35
Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin
Alaeddine Djillani, Mariel Piétri, Jean Mazella, et al.
Pharmacology & Therapeutics (2018) Vol. 194, pp. 185-198
Open Access | Times Cited: 35
Cognitive dysfunctions in depression – underestimated symptom or new dimension?
Marek Jarema, Dominika Dudek, Andrzej Czernikiewicz
Psychiatria Polska (2014) Vol. 48, Iss. 6, pp. 1105-1116
Open Access | Times Cited: 29
Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
David J. Hellerstein, Joseph Flaxer
Core evidence (2015), pp. 49-49
Open Access | Times Cited: 24
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
Anish Shah, Joanne Northcutt
Annals of General Psychiatry (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 22
Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study
Daniela Adamo, Giuseppe Pecoraro, Massimo Aria, et al.
Pain Medicine (2019)
Closed Access | Times Cited: 22
Stability-indicating reversed-phase HPLC method development and characterization of impurities in vortioxetine utilizing LC–MS, IR and NMR
Lei Liu, Na Cao, Xing-Ling Ma, et al.
Journal of Pharmaceutical and Biomedical Analysis (2015) Vol. 117, pp. 325-332
Closed Access | Times Cited: 21
New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine
Laura Orsolini, Carmine Tomasetti, Alessandro Valchera, et al.
Expert Review of Neurotherapeutics (2016) Vol. 16, Iss. 5, pp. 483-495
Closed Access | Times Cited: 20
The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
Roger S. McIntyre
Neuropsychiatric Disease and Treatment (2017) Vol. Volume 13, pp. 2913-2919
Open Access | Times Cited: 20
Effects of Vortioxetine on depression model rats and expression of BDNF and Trk B in hippocampus
Baomin Sun, Yanhua Lv, Hua Xu, et al.
Experimental and Therapeutic Medicine (2020)
Open Access | Times Cited: 16
Desvenlafaxine for the treatment of major depressive disorder
Susan G. Kornstein, Roger S. McIntyre, Michael E. Thase, et al.
Expert Opinion on Pharmacotherapy (2014) Vol. 15, Iss. 10, pp. 1449-1463
Closed Access | Times Cited: 16
Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice
Yeshwant Kurhe, Radhakrishnan Mahesh, Thangaraj Devadoss
Psychopharmacology (2017) Vol. 234, Iss. 7, pp. 1165-1179
Closed Access | Times Cited: 16
Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea
Sang-Eun Choi, Mélanie Brignone, Seong Jin Cho, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2015) Vol. 16, Iss. 5, pp. 629-638
Closed Access | Times Cited: 12
Design, synthesis and biological evaluation of arylpropylamine derivatives as potential multi-target antidepressants
Quxiang Li, Qiang Guo, Lili Ren, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 114, pp. 117935-117935
Closed Access | Times Cited: 1
Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression
Xiangqing Xu, Yaqin Wei, Qiang Guo, et al.
Journal of Pharmacology and Experimental Therapeutics (2018) Vol. 365, Iss. 3, pp. 624-635
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top